Literature DB >> 8343951

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

B A Witthuhn1, F W Quelle, O Silvennoinen, T Yi, B Tang, O Miura, J N Ihle.   

Abstract

Erythropoietin (EPO) regulates the proliferation and differentiation of erythroid cells through interaction with its receptor (EPOR). Although EPOR is a member of the cytokine receptor superfamily and lacks a kinase domain, EPO induces tyrosine phosphorylation, which is correlated with gene transcription and mitogenesis. Here we demonstrate that EPO induces tyrosine phosphorylation of JAK2 kinase and activates its in vitro autophosphorylation. Using EPOR mutants, phosphorylation and activation of kinase activity correlate with the induction of mitogenesis. Furthermore, JAK2 physically associates with a membrane-proximal region of the EPOR cytoplasmic domain that is required for biological activity. The results support the hypothesis that JAK2 is the kinase that couples EPO binding to tyrosine phosphorylation and mitogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8343951     DOI: 10.1016/0092-8674(93)90414-l

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  274 in total

1.  Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development.

Authors:  R Wen; D Wang; C McKay; K D Bunting; J C Marine; E F Vanin; G P Zambetti; S J Korsmeyer; J N Ihle; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

2.  Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.

Authors:  K Nishigaki; C Hanson; T Ohashi; D Thompson; K Muszynski; S Ruscetti
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5.

Authors:  D Wang; R Moriggl; D Stravopodis; N Carpino; J C Marine; S Teglund; J Feng; J N Ihle
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

4.  A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction.

Authors:  C Haan; H M Hermanns; P C Heinrich; I Behrmann
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

5.  Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Authors:  P Saharinen; K Takaluoma; O Silvennoinen
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

6.  Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation.

Authors:  Claude Haan; Peter C Heinrich; Iris Behrmann
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

7.  Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells.

Authors:  P A Tilbrook; E Ingley; J H Williams; M L Hibbs; S P Klinken
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

8.  Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Authors:  Jennifer M Green; Karen Leu; Angela Worth; Richard B Mortensen; David K Martinez; Peter J Schatz; Don M Wojchowski; Peter R Young
Journal:  Exp Hematol       Date:  2012-03-06       Impact factor: 3.084

Review 9.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

10.  Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies.

Authors:  G Packham; E L White; C M Eischen; H Yang; E Parganas; J N Ihle; D A Grillot; G P Zambetti; G Nuñez; J L Cleveland
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.